Risk of Tuberculosis After Achieving HIV Virological Suppression on Antiretroviral Therapy: A Danish Nationwide Prospective Cohort Study Get access

• Abstract
• Supplementary data

High-level Dolutegravir Resistance Selection on Dolutegravir/Lamivudine Free

• Extract

Plasma Human Immunodeficiency Virus 1 RNA and CD4⁺ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study Free

• Abstract
• Supplementary data

Long-Acting Cabotegravir and Rilpivirine: Innovation, New Challenges, and Opportunities Free

• Extract

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial Open Access

• Abstracts
• Supplementary data

Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment–Experienced People Living With Human Immunodeficiency Virus Free

• Abstract
• Supplementary data

Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019 Free

• Abstract
• Supplementary data

Routine Screening of Anal Cytology in Persons With Human Immunodeficiency Virus and the Impact on Invasive Anal Cancer: A Prospective Cohort Study Free

• Abstract
• Supplementary data

The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial Get access

• Abstract

Clinical Implications of Genotypic Resistance to the Newer Antiretroviral Drugs in HIV-1–Infected Patients with Virological Failure Get access

• Abstract

Bronchiolitis Obliterans Organizing Pneumonia Associated with Acute Mycoplasma pneumoniae Infection Get access

• Abstract

Hepatitis C Virus Infection and Progression of Infection Due to Human Immunodeficiency Virus Get access